SEGMENT INFORMATION (Details) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Segment Reporting Information [Line Items] | |||
| Total revenues | $ 179,278,000 | $ 116,882,000 | $ 120,242,000 |
| Less: | |||
| Cost of product sales | 18,647,000 | 7,110,000 | 1,749,000 |
| Provision for income taxes | 881,000 | ||
| Net income (loss) | 17,485,000 | (25,091,000) | (58,573,000) |
| Single reportable segment | |||
| Segment Reporting Information [Line Items] | |||
| Total revenues | 179,278,000 | 116,882,000 | 120,242,000 |
| Less: | |||
| Employee related expenses | 69,807,000 | 63,429,000 | 69,477,000 |
| Commercial related expenses | 26,996,000 | 24,310,000 | 23,846,000 |
| Cost of product sales | 18,647,000 | 7,110,000 | 1,749,000 |
| Consultants and third-party services | 15,532,000 | 17,942,000 | 22,218,000 |
| Outside clinical trial related expenses | 10,978,000 | 9,694,000 | 29,981,000 |
| Other segment items | 13,126,000 | 14,888,000 | 28,521,000 |
| Interest expense, net | 5,826,000 | 4,600,000 | 3,023,000 |
| Provision for income taxes | 881,000 | ||
| Net income (loss) | $ 17,485,000 | $ (25,091,000) | $ (58,573,000) |
| X | ||||||||||
- Definition Amount of commercial related expenses. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for consultants and third-party services. No definition available.
|
| X | ||||||||||
- Definition Amount of outside clinical trial related expenses. No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net amount of operating interest income (expense). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|